Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 5Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Breast Neoplasms 2Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hodgkin Disease 1Brain Neoplasms 1

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × Genistein × Clear all
NCT01489813 2025-02-05

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

Emory University

Phase 2 Completed
36 enrolled 7 charts
Genitourinary

Urinary Bladder Neoplasms

NCT00118040 2021-06-10

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled 24 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡